Skip to content

Public FDA record

Z-0660-2022: The Optima Coil System consists of an implantable embolization coil comprised of a platinum-tungsten allo

Recall record Z-0660-2022 for BALT USA, LLC. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-0660-2022
Company in FDA record
BALT USA, LLC
FDA record creation date
Feb 22, 2022
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

Due to Label/Pouch mix-up. Pouches incorrectly labeled. Incorrect shelf carton label or pouch label due to inadequate manufacturing line clearance. As a result of this labeling mix-up, there is the possibility of inadvertently selecting the incorrect coil size for the procedure potentially causing some harms like vessel damage, an inability to treat with said device and potential rupture of the aneurysm.

Source facts

Action
On 01/04/2022, the firm sent an "URGENT FIELD SAFETY NOTICE (FSN)/PRODUCT RECALL" letter via email to customers notifying them of the labeling mix-up which presents a high risk to patient safety and product performance, with the possibility that the user could inadvertently select the wrong size coil for a procedure. Customer/Distributors are instruction to: -Inform their customers about the notice; -Identify and locate the affected products -Collect and put in quarantine the affected products and return them to the Recalling Firm through the Return Material Authorization procedure by contacting the Recalling Firm's Customer Service Department. -Inform the Recalling Firm about the status of every unit of the affected products. -Fulfill the Notice of receipt then return to the Recall Firm via the indicated contact For Hospital Staff: -Within their hospital, inform all Safety Officers, Pharmacists, Head of Neuroradiology and the Neuroradiology Department Staff as well as any other person if deemed necessary. -Identify and locate all affected products and cease or stop using. -Collect and put in quarantine all affected products and return them to their local distributor as per its return procedure; -Inform their local distributor and the Recalling Firm about the status of every unit of affected product. -Contact their local distributor or the Recalling Firm for any additional informaiton. For questions or assistance, contact Quality Department at: email QA@balt-usa.com address: 29 Parker Suite 100, Irvine CA 92618, USA Telephone number: 949-788-1443 or Fax 949-788-1444
Initiated
2022-01-04
Root cause
Process control
Distribution
Worldwide distribution - U.S. Nationwide distribution in the states of FL and MD. The countries of Denmark, France, Germany, Lebanon, Netherlands, Sweden, Peru, Portugal, Slovenia, Spain, and United Arab Emirates.
Recall number
Z-0660-2022
Recall status
Open, Classified
CDRH record ID
191293
FDA record created
2022-02-22
Recall event number
89338

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗